secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001654954-23-006220
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q1 revenue up 45% to $5.5M; net loss widens to $6.4M
-------------------------------------------------------------

- Revenue $5.5M (+45% YoY); gross margin 70%; net loss $6.4M ($0.007/share) vs $3.9M loss a year ago.
- Diagnostic segment revenue $0.4M (+300% YoY); Therapeutic segment $5.1M (+38% YoY).
- Cash and securities $147.5M; cash used in Q1 was $8.3M including $4.0M TRUFORMA licensing fees.
- Paid $250k non-refundable deposit to exercise acquisition option for Structured Monitoring Products (VetGuardian).
- Amended Georgia lease to add 6,000 sq ft for TRUFORMA cartridge manufacturing; TRUVIEW digital microscopy system launch planned in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423006220/0001654954-23-006220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495423006220/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-006220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer